Leadership
Corporate Governance

David-Alexandre C. Gros, MD | Chief Executive Officer
Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

Steven Perrin, PhD | President and Chief Scientific Officer
Dr. Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc. before joining Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) He has 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the world’s largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.

Jeff Bornstein, MD | Chief Medical Officer
Dr. Bornstein has served as the Chief Medical Officer of Eledon Pharmaceuticals since April 2021. Prior to joining Eledon, he served as Vice President, Head of Clinical Sciences, Gastroenterology at Takeda Pharmaceuticals, and he has previously led development programs at Biogen, Gilead Sciences, Elan Pharmaceuticals, and several early stage biotechs. Dr. Bornstein earned his Doctor of Medicine and completed his residency in internal medicine at McGill University. He also completed a fellowship in gastroenterology at Duke University Medical Center where he subsequently served on the faculty as an Assistant Professor of Medicine.

Amanda Hayden | Vice President, Clinical Operations
Ms. Hayden joined Eledon in 2021 as Executive Director, Clinical Operations and was promoted to Vice President, Clinical Operations in August 2022. Prior to joining Eledon, Ms. Hayden was Senior Director, Global Clinical Services at Alkermes, where she established and led the Study Start Up, Clinical Systems & Documentation and Data Visualizations departments. During her tenure at Alkermes, Ms. Hayden led Inspection Readiness across multiple late-stage assets, including Lybalvi ®, and chaired the R&D Employee Engagement Committee. Prior to Alkermes, Ms. Hayden was Associate Director, Clinical Operations at Lantheus Medical Imaging, where she oversaw Clinical Operations and was responsible for process and staff development. Ms. Hayden began her career as a Clinical Research Associate at Certus International, and held Project and Program Leadership roles within Agenus Biotechnology and Millennium Pharmaceuticals. Ms. Hayden completed her bachelor’s degree in Communications at Plymouth State University.

John Herberger | Vice President, Technical Operations
Mr. Herberger has served as Vice President, Technical Operations of Eledon since May 2022. Prior to joining Eledon, Mr. Herberger served as Senior Director, Manufacturing Science & Technology of Spark Therapeutics. In this role he led the development of platform processes, and technology transfer as key enablers to gene therapy portfolio advancement. Prior to joining Spark Therapeutics, he served 21 years at Amgen where he held numerous leadership roles in drug delivery & formulation, device development, technology transfer and global operations. Mr. Herberger previously served on the University of Rhode Island College of Environmental & Life Sciences Dean’s Advisory Council and Bio Science Leaders Forum. Prior to joining Amgen, Mr. Herberger was a Research Scientist at Alkermes Inc., where he contributed to the development of novel drug delivery systems and authored several publications and patents in the field. Mr. Herberger began his career at the Institute of Molecular Biology where he was a founding member of this start-up biotech company which worked to develop soft tissue, bone and nerve regeneration therapies.

David Hovland, PhD | Chief Regulatory Officer

Paul Little | Chief Financial Officer

Carmen Mak, PhD | Vice President, Biometrics

Bryan Smith | General Counsel
Toolkit
Print Page | Email Alerts | RSS Feeds | Contact |